Quantcast

Latest Cadence Pharmaceuticals Inc. Stories

2011-06-02 07:00:00

SAN DIEGO, June 2, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that the company's President and CEO Ted Schroeder will present the company's corporate overview on Thursday, June 9, 2011 at 1:30pm Eastern Time (10:30am Pacific Time) during the Jefferies 2011 Global Healthcare Conference at the Grand Hyatt...

2011-05-05 06:00:00

SAN DIEGO, May 5, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, 2011. During the first quarter of 2011, Cadence commercially launched OFIRMEV(TM) (acetaminophen) injection, the first and only intravenous formulation of acetaminophen to be approved...

2011-04-28 07:30:00

SAN DIEGO, April 28, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its first quarter ended March 31, 2011 financial results on Thursday, May 5, 2011. Cadence management will host a conference call and live webcast to discuss the financial results on Thursday, May 5, 2011 at 5:30 am...

2011-04-26 15:00:00

SAN DIEGO, April 26, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present a corporate overview at the following investment conferences during the month of May: Deutsche Bank's 36th Annual Health Care Conference at the InterContinental Hotel...

2011-03-03 22:00:00

SAN DIEGO, March 3, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the fourth quarter and year ended December 31, 2010. During the fourth quarter of 2010, Cadence received marketing approval for OFIRMEV(TM) (acetaminophen) injection from the U.S. Food and Drug Administration (FDA)....

2011-03-02 15:00:00

SAN DIEGO, March 2, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Wednesday, March 9, 2011 at 8:00am Eastern Time (5:00am Pacific Time) during the Cowen and Company 31st Annual Health Care...

2011-02-25 15:00:00

SAN DIEGO, Feb. 25, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2010 financial results on Friday, March 4, 2011. Cadence management will host a conference call and live webcast to discuss the financial results on Friday,...

2011-02-08 15:00:00

SAN DIEGO, Feb. 8, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company will present a corporate overview at the following investment conferences in February: -- BIO CEO & Investor Conference Date: Tuesday, February 15, 2011...

2011-01-18 06:30:00

SAN DIEGO, Jan. 18, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced the launch of OFIRMEV(TM) (acetaminophen) injection, the first and only intravenous (IV) formulation of acetaminophen to be approved in the United States. The U.S. Food and Drug Administration (FDA) approved OFIRMEV in November 2010 for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. OFIRMEV...

2010-12-13 07:30:00

SAN DIEGO, Dec. 13, 2010 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that its underwriters partially exercised their over-allotment option in connection with its previously announced public offering that priced on November 11, 2010, by purchasing an additional 1,000,000 shares of its common stock at a public offering price of $8.00 per share. Including the over-allotment shares purchased, Cadence sold a total of 12,500,000 shares in the offering,...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'